Autostimulatory mechanisms in myeloid leukemogenesis.

Autor: Schrader, J. W., Leslie, K. B., Ziltener, H. J., Schrader, S.

Publikováno v: Journal of Cellular Biochemistry; May1987, Vol. 34 Issue 1, p39-46, 8p

Insulin receptor substrate-2 is the major 170-kDa protein phosphorylated on tyrosine in response to cytokines in murine lymphohemopoietic cells.

Autor: Welham, M J, Bone, H, Levings, M, Learmonth, L, Wang, L M, Leslie, K B, Pierce, J H, Schrader, J W

Publikováno v: Journal of Biological Chemistry; January 1997, Vol. 272 Issue: 2 p1377-81, 5p

Growth factor gene activation and clonal heterogeneity in an autostimulatory myeloid leukemia

Autor: Leslie, K B, Schrader, J W

Publikováno v: Molecular and Cellular Biology; June 1989, Vol. 9 Issue: 6 p2414-2423, 10p

Co-targeting SOS1 enhances the antitumor effects of KRAS ^G12C inhibitors by addressing intrinsic and acquired resistance.

Autor: Thatikonda V; Boehringer Ingelheim RCV, Vienna, Austria. vthatikonda@exscientia.co.uk.; Exscientia, Vienna, Austria. vthatikonda@exscientia.co.uk., Lyu H; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jurado S; Boehringer Ingelheim RCV, Vienna, Austria., Kostyrko K; Boehringer Ingelheim RCV, Vienna, Austria., Bristow CA; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Albrecht C; Boehringer Ingelheim RCV, Vienna, Austria., Alpar D; Boehringer Ingelheim RCV, Vienna, Austria., Arnhof H; Boehringer Ingelheim RCV, Vienna, Austria., Bergner O; Boehringer Ingelheim RCV, Vienna, Austria., Bosch K; Boehringer Ingelheim RCV, Vienna, Austria., Feng N; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gao S; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gerlach D; Boehringer Ingelheim RCV, Vienna, Austria., Gmachl M; Boehringer Ingelheim RCV, Vienna, Austria., Hinkel M; Boehringer Ingelheim RCV, Vienna, Austria., Lieb S; Boehringer Ingelheim RCV, Vienna, Austria., Jeschko A; Boehringer Ingelheim RCV, Vienna, Austria., Machado AA; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Madensky T; Boehringer Ingelheim RCV, Vienna, Austria., Marszalek ED; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mahendra M; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Melo-Zainzinger G; Boehringer Ingelheim RCV, Vienna, Austria., Molkentine JM; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jaeger PA; Boehringer Ingelheim RCV, Vienna, Austria., Peng DH; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Schenk RL; Boehringer Ingelheim RCV, Vienna, Austria., Sorokin A; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Strauss S; Boehringer Ingelheim RCV, Vienna, Austria., Trapani F; Boehringer Ingelheim RCV, Vienna, Austria., Kopetz S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vellano CP; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Petronczki M; Boehringer Ingelheim RCV, Vienna, Austria., Kraut N; Boehringer Ingelheim RCV, Vienna, Austria., Heffernan TP; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Marszalek JR; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pearson M; Boehringer Ingelheim RCV, Vienna, Austria., Waizenegger IC; Boehringer Ingelheim RCV, Vienna, Austria., Hofmann MH; Boehringer Ingelheim RCV, Vienna, Austria. marco.hofmann@boehringer-ingelheim.com.

Publikováno v: Nature cancer [Nat Cancer] 2024 Sep; Vol. 5 (9), pp. 1352-1370. Date of Electronic Publication: 2024 Aug 05.

Eine strukturelle Evaluierung medizinalchemischer Strategien gegen Wirkstoffresistenzen.

Autor: Agnello, Stefano¹, Brand, Michael¹, Chellat, Mathieu F.¹, Gazzola, Silvia¹, Riedl, Rainer¹ rainer.riedl@zhaw.ch

Publikováno v: Angewandte Chemie. 3/11/2019, Vol. 131 Issue 11, p3336-3383. 48p.